Welcome to our dedicated page for Tenax Therapeutics SEC filings (Ticker: TENX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Tenax Therapeutics, Inc. (TENX) provides access to the company’s official disclosures as a Nasdaq-listed, Phase 3, development-stage pharmaceutical company. Through these filings, Tenax reports material events, clinical and corporate milestones, and periodic financial results related to its cardiopulmonary drug development programs.
Recent Form 8-K filings have documented key developments in the company’s PH-HFpEF program. These include announcements that the European Patent Office issued an Intention to Grant a patent covering TNX‑103 (oral levosimendan), other levosimendan formulations, and its active metabolites for use in PH-HFpEF, and that Tenax completed a prespecified blinded sample size re-estimation in the registrational Phase 3 LEVEL trial of TNX‑103 in the United States and Canada. Other 8‑K filings describe the initiation of the global Phase 3 LEVEL‑2 study and amendments to the company’s license agreement with Orion Corporation, expanding Tenax’s rights to develop, commercialize, and manufacture orally administered levosimendan products.
Filings also include earnings-related 8-Ks, where Tenax furnishes press releases detailing quarterly financial results and corporate updates. These disclosures discuss research and development spending on the LEVEL and LEVEL‑2 trials, general and administrative expenses, and the company’s cash position and funding outlook, all within the framework of SEC reporting requirements.
On this page, users can review Tenax’s SEC submissions, including current reports and other documents that may be filed over time. Stock Titan enhances this information with AI-powered summaries that explain the significance of complex filings, highlight clinical and IP milestones, and help readers quickly identify items related to Phase 3 trial progress, licensing arrangements, and the company’s PH-HFpEF strategy. This resource supports investors and researchers seeking a structured view of TENX’s regulatory and financial reporting history.
RTW Investments, LP and Roderick Wong, M.D. report a 9.99% beneficial stake in Tenax Therapeutics, Inc. common stock. They report beneficial ownership of 650,968 shares, including warrants to purchase 272,622 shares, subject to a 9.99% ownership cap in the warrant terms.
The ownership percentage is calculated using 6,243,575 Tenax shares outstanding as of November 11, 2025, as disclosed in the company’s Form 10-Q. Voting and investment power over these shares is shared, with no sole voting or dispositive power reported. The securities are stated as held in the ordinary course of business and not for the purpose of influencing control of Tenax.
Morgan Stanley reports beneficial ownership of 596,376 shares of Tenax Therapeutics, Inc. common stock, representing 9.6% of the class. These shares are held with shared voting power over 592,316 shares and shared dispositive power over 596,376 shares.
Morgan Stanley Capital Services LLC reports beneficial ownership of 592,316 shares, or 9.5% of the common stock class, all with shared voting and dispositive power. The firms state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Tenax.
Tenax Therapeutics, Inc.’s interim CFO, Thomas McGauley, reported a stock option covering 50,000 shares of common stock at an exercise price of
According to the footnote, the option vests with 50% on
Tenax Therapeutics director Michael H. Davidson reported a new equity award and his current holdings in company securities. On 01/09/2026, he was granted a stock option to buy 30,000 shares of Tenax Therapeutics common stock at an exercise price of $13.3 per share, expiring on 01/09/2036. Following this grant, he holds 2,881 shares of common stock directly.
He also reports several existing derivative positions, including stock options covering 100,000 shares exercisable from 12/10/2025 to 12/10/2034, and options for 80,000 shares exercisable from 07/01/2026 to 07/01/2035, plus smaller option positions. In addition, he holds a pre-funded warrant for 47,500 shares with a $0.01 exercise price and no expiration date, and a warrant for 25,000 shares with a $4.5 exercise price that can terminate based on Phase 3 LEVEL Study topline data timing or on August 8, 2029.
Tenax Therapeutics CEO Christopher Thomas Giordano received a grant of 450,000 stock options on January 9, 2026. The options give him the right to buy common stock at an exercise price of $13.3 per share.
According to the vesting terms, 25% of the underlying shares vest and become exercisable on January 9, 2027, and the remaining shares vest in equal monthly installments over the following 36 months, subject to his continued employment. After this grant, he directly holds 2,605 shares of common stock and several other stock option awards with various expiration dates extending through 2035.
Tenax Therapeutics, Inc. reported a new equity award to its chief medical officer and director, Stuart Rich. On January 9, 2026, he received a grant of stock options to buy 250,000 shares of common stock at an exercise price of $13.3 per share. These options vest over time, with 25% becoming exercisable on January 9, 2027 and the remaining shares vesting in equal monthly installments over the following 36 months, conditioned on his continued employment.
After this grant, he holds 5,266 shares of common stock directly, plus additional shares held indirectly through several family trusts. The filing states that he has voting or trustee roles with these trusts but disclaims beneficial ownership of their shares except to the extent of any pecuniary interest.
Tenax Therapeutics director Gerald T. Proehl reported an equity award and updated holdings. On January 9, 2026, he received a stock option to buy 30,000 shares of common stock, representing 3,000 derivative securities acquired, with an exercise price of $13.30 per share and an expiration date of January 9, 2036.
After this grant, he directly holds 1,667 shares of common stock, stock options covering 30,000, 100,000 and 80,000 shares under various prior grants, and a pre-funded warrant for 31,654 shares with a $0.01 exercise price and no expiration date. He also holds a warrant for 16,660 shares at a $4.50 exercise price that will expire based on the timing of topline data from Tenax’s Phase 3 LEVEL Study or, at the latest, on August 8, 2029.
Tenax Therapeutics director June Sherie Almenoff reported a new stock option grant and her current equity holdings in a Form 4 filing. On January 9, 2026, she was granted a stock option for 30,000 shares of common stock at an exercise price of $13.30 per share. This option becomes exercisable on January 9, 2027 and expires on January 9, 2036, and was reported as held directly.
The filing also lists previously awarded stock options held directly, covering 100,000 shares (exercisable from December 10, 2025 to December 10, 2034), 80,000 shares (exercisable from July 1, 2026 to July 1, 2035), and two very small option positions of 4 shares each. In addition, 1,993 shares of common stock are reported as held indirectly through Meadowlark Management, LLC, with a statement that Almenoff disclaims beneficial ownership except to the extent of her pecuniary interest.
Tenax Therapeutics director Declan Doogan reported a new stock option grant. The Form 4 shows that on 01/09/2026 he received a stock option to buy 30,000 shares of Tenax common stock at an exercise price of
In addition to this grant, the filing lists previously awarded stock options covering 100,000 shares exercisable from
Tenax Therapeutics director Robyn Hunter reported a new stock option grant in a Form 4 filing. On January 9, 2026, Hunter received stock options to buy 30,000 shares of common stock at an exercise price of $13.30 per share, with no cash paid for the option itself.
The options become exercisable on January 9, 2027 and expire on January 9, 2036. After this grant, Hunter directly holds 30,000 of these newly reported derivative securities, alongside other previously granted stock options in Tenax Therapeutics.